Impact of apolipoprotein ɛ4–cerebrospinal fluid beta‐amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment
Abstract
The majority of studies relating amyloid pathology with brain volumes have been cross‐sectional. Apolipoprotein ɛ4 (APOE ɛ4), a genetic risk factor for Alzheimer's disease, is also known to be associated with hippocampal volume loss. No studies have considered the effects of amyloid pathology and APOE ɛ4 together on longitudinal volume loss.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Sep 01, 2011
- Source ID
- 10.1016/j.jalz.2010.12.010
Entities
People
- Anthony Gamst
- Clifford Jack
- Danielle J. Harvey
- Diana Truran‐sacrey
- Duygu Tosun
- Eric M. Reiman
- Gloria C. Chiang
- Laurel A. Beckett
- Michael W. Weiner
- Nick C. Fox
- Norbert Schuff
- Paul M. Thompson
- Paul S. Aisen
- Philip S Insel
- Ron C. Petersen
- Sky T. Raptentsetsang
- William J. Jagust
Organizations
- Alzheimer's Association
- Alzheimer's Research UK
- AstraZeneca
- Dana Foundation
- GSK
- Loma Linda University Medical Center
- Mayo Medical School
- Medical Research Council
- Merck & Co.
- National Institute for Health and Care Research
- National Institute of Biomedical Imaging and Bioengineering
- National Institute on Aging
- National Institutes of Health
- Northern California Institute for Research and Education
- Pfizer
- UCL Queen Square Institute of Neurology
- United States Department of Defense
- University of Arizona
- University of California, Davis
- University of California, Los Angeles
- University of California, San Diego
- University of California, San Francisco